Association between weight reduction achieved with tirzepatide and quality of life in adults with obesity: Results from the SURMOUNT-1 study

What Was Tested

The paper reports a study of Tirzepatide, published as a randomized controlled trial.

The SURMOUNT-1 trial investigated effects of tirzepatide, a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, on body weight in participants with obesity or overweight.

This analysis evaluated changes in patient-reported outcomes (PROs) assessing physical function, psychosocial well-being, and overall health aspects of participants' health-related quality of life (HRQoL) in SURMOUNT-1.

Who Took Part

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

PRO instruments included the Impact of Weight on Quality of Life-Lite Clinical Trials version (IWQOL-Lite-CT), Short Form Survey-36 version 2 (SF-36v2) and EQ-5D-5L.

Relevant PROs were evaluated for participants with or without physical or psychosocial limitations at baseline, as measured by Patient Global Impression of Status for physical activity (PGIS) and Patient Health Questionnaire-2 (PHQ-2), respectively.

How the Study Was Run

The design is described as randomized and double-blind.

Random assignment meant chance, not the researchers, decided who got Tirzepatide and who got the comparison, which limits bias.

As a double-blind Tirzepatide study, the assignments were hidden from both participants and investigators until the end.

What Was Measured

The subject headings attached to it are Anti-Obesity Agents, Glucagon-Like Peptide-1 Receptor, Obesity, Overweight, Patient Reported Outcome Measures, Quality of Life and Weight Loss.

The authors tagged it with the keywords GIP, GLP‐1, obesity therapy and patient‐reported outcomes.

What This Means in Plain Language

The paper is a randomized and double-blind study of Tirzepatide.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2025 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Tirzepatide compound page, all human trials.